001     169289
005     20240229133647.0
024 7 _ |a 10.1093/gerona/glaa128
|2 doi
024 7 _ |a pmid:32459845
|2 pmid
024 7 _ |a 1079-5006
|2 ISSN
024 7 _ |a 1758-535X
|2 ISSN
024 7 _ |a altmetric:82949893
|2 altmetric
037 _ _ |a DKFZ-2021-01386
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Chen, Li-Ju
|0 P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe
|b 0
|e First author
|u dkfz
245 _ _ |a Systematic Review and Meta-Analysis on the Associations of Polypharmacy and Potentially Inappropriate Medication With Adverse Outcomes in Older Cancer Patients.
260 _ _ |a Oxford [u.a.]
|c 2021
|b Oxford Univ. Pr.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1637159680_23141
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a C070#LA:C070#
520 _ _ |a Both polypharmacy and potentially inappropriate medication (PIM) intake are highly prevailing in older cancer patients. However, only studies on the association of polypharmacy and postoperative complications have been meta-analyzed previously.A systematic review and a meta-analysis of prospective/retrospective observational studies reporting associations of polypharmacy or PIM with at least one out of five predefined adverse health outcomes in a population of older cancer patients (≥60 years) were carried out. PubMed and Web of Science were used to search for relevant studies published between January 1991 and March 2020. Data were pooled by adopting a random-effects model.Overall, 42 publications were included in the systematic review. Meta-analyses could be performed on 39 studies about polypharmacy and 13 studies about PIM. Polypharmacy was found to be statistically significantly associated with all-cause mortality (risk ratio [95% confidence interval]: 1.37 [1.25-1.50]), hospitalization (1.53 [1.37-1.71]), treatment-related toxicity (1.22 [1.01-1.47]), and postoperative complications (1.73 [1.36-2.20]). The association of polypharmacy with prolongation of hospitalization was not statistically significant at the p < .05 significance level (1.62 [0.98-2.66]). With respect to PIM, a statistically significant association with all-cause mortality (1.43 [1.08-1.88]) was observed but not with other adverse outcomes.Polypharmacy was found to be associated with several adverse outcomes and PIM use with all-cause mortality in older cancer patients. However, these results should be interpreted with caution because about three-quarters of the studies identified did not adjust for comorbidity and are prone to confounding by indication.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Adverse drug reaction
|2 Other
650 _ 7 |a Geriatric oncology
|2 Other
650 _ 7 |a Hospitalizations
|2 Other
650 _ 7 |a Mortality
|2 Other
650 _ 7 |a Postoperative complications
|2 Other
700 1 _ |a Trares, Kira
|0 P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea
|b 1
|u dkfz
700 1 _ |a Laetsch, Dana Clarissa
|0 P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57
|b 2
|u dkfz
700 1 _ |a Nguyen, Thi Ngoc Mai
|0 P:(DE-He78)abb10265fc5b7b424eee557e979d490f
|b 3
|u dkfz
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 4
|u dkfz
700 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.1093/gerona/glaa128
|g Vol. 76, no. 6, p. 1044 - 1052
|0 PERI:(DE-600)2043927-1
|n 6
|p 1044 - 1052
|t The journals of gerontology / A
|v 76
|y 2021
|x 1758-535X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169289
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)abb10265fc5b7b424eee557e979d490f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0130
|2 StatID
|b Social Sciences Citation Index
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1180
|2 StatID
|b Current Contents - Social and Behavioral Sciences
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J GERONTOL A-BIOL : 2019
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-28
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-28
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J GERONTOL A-BIOL : 2019
|d 2021-01-28
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21